Newly developed lignin-based hydrogel proves to be a promising tool for wound healing and controlled drug release, according to a new study. With the

New lignin-based hydrogel represents a breakthrough in the fields of wound healing and drug delivery, offering innovative solutions for improved medical treatments.

New Lens Aims to Treat Contact Lens Wearers Who Suffer from Seasonal Allergies

As the industry continues to trend toward a more patient-centric approach, we see an increasing buzz around the development and utilization of wearable injectors, also known as on-body delivery systems (OBDS)—the next evolution in needle-based drug delivery products.

Manufacturing

Explore how on-target precision therapies improve patient outcomes and drug tolerability.

Historically, the intestinal lymphatics were considered passive conduits for fluids, immune cells, dietary lipids, lipid soluble vitamins, and lipophilic drugs. Studies of intestinal lymphatic drug delivery in the late 20th century focused primarily on the drugs’ physicochemical properties, especially high lipophilicity, that resulted in intestinal lymphatic transport. More recent discoveries have changed our traditional view by demonstrating that the lymphatics are active, plastic, and tissue-specific players in a range of biological and pathological processes, including within the intestine. These findings have, in turn, inspired exploration of lymph-specific therapies for a range of diseases, as well as the development of more sophisticated strategies to actively deliver drugs or vaccines to the intestinal lymph, including a range of nanotechnologies, lipid prodrugs, and lipid-conjugated materials that "hitchhike" onto lymphatic transport pathways. With the increasing development of novel therapeutics such as biologics, there has been interest in whether these therapeutics are absorbed and transported through intestinal lymph after oral administration. Here we review the current state of understanding of the anatomy and physiology of the gastrointestinal lymphatic system in health and disease, with a focus on aspects relevant to drug delivery. We summarize the current state-of-the-art approaches to deliver drugs and quantify their uptake into the intestinal lymphatic system. Finally, and excitingly, we discuss recent examples of significant pharmacokinetic and therapeutic benefits achieved via intestinal lymphatic drug delivery. We also propose approaches to advance the development and clinical application of intestinal lymphatic delivery strategies in the future.

Raising deep concern over the partnership between Swiggy Instamart and PharmEasy for a rapid drug delivery model, the All India Organization of Chemists and Druggists (AIOCD) has apprised the Drug Controller

Companies are hoping to use the vesicles to package small-molecule, protein, and RNA drugs or even use them as therapies themselves

The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt.

A peptide comprising a sequence for opening a tight junction of an epithelial surface and optionally a cell penetrating sequence; and related compositions, optionally comprising further pharmaceutical agents; and related methods.

An assembly for a counter mechanism for a drug delivery device is described comprising a drive member, wherein the drive member is adapted and arranged to be rotated in a first rotational direction and to be prevented from rotation in a second rotational direction which direction is opposite to the first rotational direction, an advancing member adapted and arranged to be axially moved and rotated with respect to the drive member, wherein the advancing member is adapted and arranged to mechanically cooperate with the drive member such that the drive member is rotated in the first rotational direction, and a display member which is configured to count a number of doses and to display the counted number of doses, wherein the assembly is adapted and arranged such that rotation of the drive member in the first rotational direction is converted into a counting movement of the display member. Furthermore, a drug delivery device comprising the assembly is described.

An assembly for a drug delivery device (1) is proposed, comprising a housing (13) having a proximal end and a distal end, a dose member (23) which is displaceable in the proximal direction with respect to the housing for setting of a dose of a drug, a clutch member (28) which is displaced in the proximal direction with respect to the housing when setting the dose, and a stop member (30) configured to define a clutch stop position for the proximal displacement of the clutch member with respect to the housing, with the clutch member, when in the clutch stop position, being prevented from further displacement in the proximal direction with respect to the housing, wherein the clutch member and the dose member are configured to mechanically cooperate with one another when the clutch member is in the clutch stop position, thereby preventing further displacement of the dose member in the proximal direction with respect to the housing during setting of the dose. Furthermore, a drug delivery device (1) is proposed.

An add-on logging device (100, 300) mounted to a drug delivery device is turned on when the cap is removed. After a given amount of time in inactivity the sensor means of the add-on device is turned off automatically to save energy. If the user takes a dose of drug this is not detected as the add-on device is only turned on when the cap is removed. According to the present invention a warning message is provided when the cap is re-mounted after the sensor means has been turned off automatically, the warning message indicating to a user that an expelled dose may not have been detected.

The invention is directed to a dose indicating mechanism for drug delivery device (1) configured for the delivery of a medicament contained in single medicament cartridge (2), the medicament comprising at least one first drug and one second drug, wherein the dose indicating mechanism comprises a body (3), a dose dial component (7) configured to move relative to the body (3) during dose setting and first dose indicator means (10) configured to display a set dose of the medicament and/or of first drug in dependence of the displacement of dose dial component (7) during dose setting. In order to provide the user with further information, a second dose indicator means (15) is provided that is configured to display a set dose of the second drug during dose setting. The invention is also directed to a respective drug delivery device.

A drug delivery device is provided herein, the device including a reservoir for containing a medicament. The medicament includes a suspension of solids in a liquid carrier. The device also includes a needle having a distal end for injection into a patient, a proximal end in communication with the reservoir, and a lumen extending between the distal and proximal ends. A path is defined from the reservoir to the distal end of the needle through the lumen, the path having an inner diameter that decreases in a proximal to distal direction along at least a portion thereof. Advantageously, with the subject invention, a flow path may be defined which provides a more gradual transition in diameter from the reservoir to a distal tip of the needle. In this manner, changes in velocity of the suspension may be less abrupt than in the prior art, thus better maintaining solid particles in the suspension.

A drug delivery balloon apparatus is disclosed herein, comprising: (a) at least two lumens, comprising a first lumen and a second lumen, (b) a balloon inflation port in fluid communication with the first lumen, (c) a drug delivery port in fluid communication with the second lumen, (d) a guidewire port in fluid communication with the second lumen, wherein the second lumen is configured to receive both a guidewire and a drug solution, (e) an occlusion balloon, (I) a drug delivery balloon, where the occlusion balloon and the drug delivery balloon are in fluid communication with the first lumen, (g) one or more drug delivery channels extending the length of the second lumen, and (h) one or more drug delivery ducts extending from the one or more drug delivery channels to an exterior surface of the second lumen.

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, nutraceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.

A transdermal drug delivery device comprises: a reservoir for holding a drug; and at least one microneedle in fluid communication with the reservoir through which the drug can be delivered transdermally, wherein the transdermal drug delivery device is concealed from view during operation thereof.

Secretary for Constitutional & Mainland Affairs Erick Tsang today visited the temporary operation centre for the special scheme for delivering urgently needed prescription medication to Hong Kong people in Guangdong and Fujian.

Under the compulsory quarantine arrangements, many Hong Kong people who are staying in Guangdong and Fujian provinces are unable to attend follow-up consultations in Hong Kong to replenish their prescription medication and return to the Mainland on the same day.

The Government introduced a special scheme on February 24 to deliver medicine to them, with priority given to those who would run out of prescription medication by end-April.

Mr Tsang was pleased to learn that as of April 29, prescription medication deliveries had been made to more than 7,600 Hong Kong residents in need.

He thanked the Hong Kong Federation of Trade Unions for offering voluntary services for the drug delivery scheme with its well-established service networks on the Mainland.

Mr Tsang also thanked the Pharmaceutical Society of Hong Kong and Hong Kong Pharmaceutical Care Foundation for deploying pharmacists to the temporary operation centre to help verify drug records and patients' information.

During his visit, he gave encouragement to participating volunteers and thanked them for their support for the scheme.

Mr Tsang said as the expiry date for the Compulsory Quarantine of Certain Persons Arriving at Hong Kong Regulation has been extended to June 7, the special scheme will be extended and give priority to cases in which prescription drugs will run out on or before that date.

Call 2343 2255 for enquiries about the scheme.

Title: Magnetic Fields Concentrate Drug Delivery
Category: Health News
Created: 4/23/2010 6:10:00 PM
Last Editorial Review: 4/26/2010 12:00:00 AM

The launch of the renamed, newly independent company follows its acquisition by Altaris Capital Partners.

COVID-19 is having varying effects on different markets within healthcare, with drug delivery systems…

Curcumin can be incorporated into stable drug formulations to improve therapeutic efficacy, according to Dr Prem Felix Siril, Principal Investigator of

Singapore : Springer, 2019.

[Place of publication not identified], SPRINGER Verlag, SINGAPOR, 2019.

Tokyo : Springer, 2019.